Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neur... Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). Mehr anzeigen
Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire NEW YORK, Dec. 6, 2024 NEW YORK, Dec. 6, 2024 /PRNewswire/...
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 PR Newswire ROCKVILLE, Md., Nov. 14, 2024 - Event will feature...
REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates PR Newswire ROCKVILLE, Md., Nov. 6, 2024 Advancement in Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for...
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., Nov. 4, 2024 ROCKVILLE, Md., Nov. 4, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it...
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights PR Newswire ROCKVILLE, Md., Oct. 30, 2024 ROCKVILLE, Md., Oct...
REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 PR Newswire ROCKVILLE, Md., Oct. 21, 2024 97% reduction in...
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting PR Newswire ROCKVILLE, Md., Oct. 18, 2024 ROCKVILLE, Md., Oct. 18, 2024 /PRNewswire/ -- REGENXBIO...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.67 | -7.99522673031 | 8.38 | 8.825 | 7.38 | 1473222 | 8.05982839 | CS |
| 4 | -1.34 | -14.8066298343 | 9.05 | 10.52 | 7.38 | 1236457 | 9.05553895 | CS |
| 12 | -3.16 | -29.0708371665 | 10.87 | 12.22 | 7.38 | 868301 | 9.59071291 | CS |
| 26 | -4.49 | -36.8032786885 | 12.2 | 15.36 | 7.38 | 703588 | 10.73697343 | CS |
| 52 | -11.84 | -60.5626598465 | 19.55 | 28.8 | 7.38 | 665914 | 13.96855499 | CS |
| 156 | -24.54 | -76.0930232558 | 32.25 | 36.35 | 7.38 | 488147 | 18.80395552 | CS |
| 260 | -33.68 | -81.3723121527 | 41.39 | 54.97 | 7.38 | 457200 | 25.54072133 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
